Primary malignant mucosal melanoma of the maxillofacial area
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments. Materials and Methods: Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients’ clinical information was reviewed retrospectively. Results: Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%. Conclusion: The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection. Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.
Abstract
Objectives: We aimed to collect and report data from all patients who have been diagnosed with mucosal malignant melanoma to obtain the epidemiology and principles of current treatments. Materials and Methods: Between January 2008 and December 2018, 20 patients underwent surgery or follow-up observations at Yonsei University Dental Hospital. The patients’ clinical information was reviewed retrospectively. Results: Seventeen of 20 patients had undergone definitive surgery, while only 6 patients received adjuvant radiotherapy or systemic therapy. Eight of 20 patients, including those that had recurrent lesions, were provided immunotherapy. The 3-year survival for all stages was 50%, with a local recurrence rate of 75% and a metastasis rate of 65%. Conclusion: The overall survival of patients receiving surgical treatment was longer than that of patients who did not undergo surgical resection. Eight of 20 patients received immunotherapy as the first-line regimen at our clinic, and those patients exhibited longer overall survival compared to patients in reported keynote studies.
참고문헌 (23)
- Andersen LJ, "Malignant melanoma of the upper respiratory tract and the oral cavity", J Otolaryngol, 21, pp.180~185 (1992)
- Alfred E. Chang, "The National Cancer Data Base report on cutaneous and noncutaneous melanoma", Cancer, 83(8), pp.1664~1678 (1998), Wiley[DOI]
- Simon Skovsted Yde, "Mucosal Melanoma: a Literature Review", Current Oncology Reports, 20(3) (2018), Springer Science and Business Media LLC[DOI]
- Valerie J. Lund, "Management Options and Survival in Malignant Melanoma of the Sinonasal Mucosa", The Laryngoscope, 109(2), pp.208~211 (1999), Wiley[DOI]
- Sapp JP, "Contemporary oral and maxillofacial pathology" (2004), Mosby
- Shiran Sun, "Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution", Oral Oncology, 74, pp.115~122 (2017), Elsevier BV[DOI]
- Marcin J. Napierała, "Mucosal melanoma — clinical presentation and treatment based on a case series", Oncology in Clinical Practice, 15(4), pp.223~230 (2019), VM Media SP. zo.o VM Group SK[DOI]
- Abraham J. Wu, "Radiotherapy After Surgical Resection for Head and Neck Mucosal Melanoma", American Journal of Clinical Oncology, 33(3), pp.281~285 (2010), Ovid Technologies (Wolters Kluwer Health)[DOI]
- National Comprehensive Cancer Network(NCCN), "NCCN clinical practice guidelines in oncology : head and neck cancers", Plymouth Meeting : NCCN;, pp.83~87 (2020)
- William M. Mendenhall, "Head and Neck Mucosal Melanoma", American Journal of Clinical Oncology, 28(6), pp.626~630 (2005), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Fernando López, "Update on primary head and neck mucosal melanoma", Head & Neck, 38(1), pp.147~155 (2016), Wiley[DOI]
- D. Gilligan, "Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses", The British Journal of Radiology, 64(768), pp.1147~1150 (1991), British Institute of Radiology[DOI]
- Holly L. Bartell, "Biochemotherapy in patients with advanced head and neck mucosal melanoma", Head & Neck, 30(12), pp.1592~1598 (2008), Wiley[DOI]
- Spiros Manolidis, "Malignant mucosal melanoma of the head and neck", Cancer, 80(8), pp.1373~1386 (1997), Wiley[DOI]
- Stanislav Lazarev, "Mucosal Melanoma of the Head and Neck: A Systematic Review of the Literature", International Journal of Radiation Oncology*Biology*Physics, 90(5), pp.1108~1118 (2014), Elsevier BV[DOI]
- Gideon Bachar, "Mucosal melanomas of the head and neck: The Princess Margaret Hospital experience", Head & Neck, 30(10), pp.1325~1331 (2008), Wiley[DOI]
- Jarad M. Martin, "Outcomes in sinonasal mucosal melanoma", ANZ Journal of Surgery, 74(10), pp.838~842 (2004), Wiley[DOI]
- Daniel Jethanamest, "Predictors of Survival in Mucosal Melanoma of the Head and Neck", Annals of Surgical Oncology, 18(10), pp.2748~2756 (2011), Springer Science and Business Media LLC[DOI]
- Antoine Moya-Plana, "Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma", Cancer Immunology, Immunotherapy, 68(7), pp.1171~1178 (2019), Springer Science and Business Media LLC[DOI]
- Omid Hamid, "Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006", British Journal of Cancer, 119(6), pp.670~674 (2018), Springer Science and Business Media LLC[DOI]
- Jeffrey Weber, "Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma", New England Journal of Medicine, 377(19), pp.1824~1835 (2017), Massachusetts Medical Society[DOI]
- Lu Si, "A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)", Translational Oncology, 12(6), pp.828~835 (2019), Elsevier BV[DOI]
- Taylor Manton, "Sinonasal Melanoma: A Single Institutional Analysis and Future Directions", Journal of Neurological Surgery Part B: Skull Base, 80(05), pp.484~492 (2019), Georg Thieme Verlag KG[DOI]